Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of ustekinumab in psoriatic arthritis
2009-012265-60Phase 3Completed
- Sponsor
- Janssen Biologics B.V.
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing ustekinumab with placebo (2 arms). Primary endpoint: ACR20 response at Week 24. Started Feb 2010; status: completed.
02
Drugs
ustekinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2009-012265-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012265-60.